Overview
Lan-lan Pang practices practicing medicine in Guangzhou, China.
Their clinical expertise encompasses EGFR Positive Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Metastatic Brain Tumor.
They are actively involved in clinical research, co-authoring 10 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Lan-lan Pang
Is Lan-lan Pang a top-rated expert for EGFR Positive Lung Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Lan-lan Pang is classified as an Experienced expert for EGFR Positive Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Lan-lan Pang participate in research or clinical trials?
Yes. Lan-lan Pang has published 10 articles and abstracts on conditions like EGFR Positive Lung Cancer. You can view a list of Lan-lan Pang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- EGFR Positive Lung CancerPang isExperienced. Learn about EGFR Positive Lung Cancer.
- Lung CancerPang isExperienced. Learn about Lung Cancer.
- Metastatic Brain TumorPang isExperienced. Learn about Metastatic Brain Tumor.
- Non-Small Cell Lung Cancer (NSCLC)
- PIK3CA-Related Overgrowth Spectrum